Development of a novel staging classification for Siewert II adenocarcinoma of the esophagogastric junction after neoadjuvant chemotherapy

Table 3 Univariate and multivariate analysis of disease-specific survival for Siewert type II adenocarcinoma of the esophagogastric junction underwent radical gastrectomy with neoadjuvant chemotherapy

	Univariate analysis			Multivariate analysis
	HR	95%CI	P value	HR	95%CI	P value
Age
< 65 yr old	1
≥ 65 yr old	1.01	0.83-1.24	0.895
Sex
Male	1			1
Female	0.75	0.56-1.01	0.060	0.75	0.55-1.01	0.056
Marital status
Married	1
Divorced or separated	1.23	0.9-1.67	0.197
Single (never married)	1.23	0.93-1.63	0.150
Widowed	1.18	0.71-1.96	0.516
Others	0.84	0.46-1.54	0.579
Race
White	1			1
Others	0.78	0.55-1.09	0.142	0.72	0.51-1.01	0.054
Year of diagnosis
2004-2009	1
2010-2015	0.96	0.78-1.18	0.699
Type of surgery
Subtotal gastrectomy	1
Total gastrectomy	1	0.78-1.28	0.985
Tumor size
< 50 mm	1
≥ 50 mm	1.08	0.86-1.35	0.504
The number of examined lymph nodes	1	0.99-1.01	0.516
yp T stage
T1	1			1
T2	1.44	0.9-2.3	0.125	1.25	0.78-2.01	0.347
T3	2.29	1.55-3.38	< 0.001	1.69	1.13-2.54	0.010
T4a	3.19	2.06-4.94	< 0.001	2.18	1.38-3.44	0.001
yp N stage
N0	1			1
N1	1.56	1.19-2.05	0.001	1.43	1.08-1.88	0.012
N2	2.22	1.7-2.92	< 0.001	1.93	1.45-2.56	< 0.001
N3	3.7	2.73-5.02	< 0.001	3.17	2.31-4.35	< 0.001
Grade
Well differentiated	1
Moderate differentiated	0.93	0.56-1.55	0.795
Low differentiated	1.53	0.93-2.49	0.091
Gx	1.11	0.58-2.1	0.759
Adjuvant chemotherapy
No	1
Yes	0.88	0.68-1.12	0.301

HR: Hazard ratio.